SPX3,931.66-67.18 -1.68%
DIA335.82-4.21 -1.24%
IXIC10,987.77-252.16 -2.24%

Barclays Maintains Overweight on Revance Therapeutics, Raises Price Target to $37

Benzinga · 11/16/2022 07:03
Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:RVNC) with a Overweight and raises the price target from $35 to $37.